Lithium shows no benefit to MND patients

Lithium shows no benefit to MND patients

(Medical Xpress)—Results from a clinical trial into amyotrophic lateral sclerosis (ALS), led by King's College London's Institute of Psychiatry show that lithium carbonate is ineffective at treating the disease.

ALS is a type of (MND). It is a neurodegenerative disease in which motor neurons in the brain and spinal cord degenerate, resulting in progressive paralysis ultimately leading to dependence on mechanical or death, usually within 3 years. A drug called riluzole is known to improve survival in patients with ALS, but the effect is moderate and there remains a pressing need for more effective treatments.

The trial, known as the 'LiCALS trial' involved 214 patients with amyotrophic lateral sclerosis (ALS – a type of MND) who were currently taking riluzole. Patients were randomly allocated daily doses of oral (107 patients), or a placebo (107 patients) and followed for 18 months.

The findings, published recently in the The Lancet Neurology, report that while lithium was safe, there was no significant increase in for patients prescribed lithium, compared to the placebo.

Previous research had found that lithium had neuroprotective effects in cells and animal models of neurodegeneration.

Professor Ammar Al-Chalabi, chief investigator of the trial from the Department of Clinical Neuroscience at King's Institute of Psychiatry, says: "A previous small study showed that lithium might slow down ALS and improve survival rates, but the result was not certain. What was needed was a definitive trial to show whether or not this was an effective treatment for patients with ALS.

"Although the results are disappointing, the trial has allowed the development of a trials network of ten centres in the UK, which will be of great benefit for rapidly testing future therapies. We are most grateful to the who took part in the trial and not only helped answer the question of whether lithium could treat ALS, but also helped in establishing a trials network. We will continue our search for novel treatments for this devastating disease."

Funded by the Motor Neurone Disease Association (MNDA), the trial was coordinated by the National Institute for Health Research (NIHR) DeNDRoN (Dementias and Network).

Dr Brian Dickie, Director of Research Development at the MND Association says: "As many people will know, when lithium was first proposed as having benefit in MND, a couple of small, short-term trials were performed to establish whether the drug had a large and rapid effect on physical changes in disease progression. This trial, by contrast, was developed to ask whether the drug had a more subtle benefit over a longer time course, as is the case with riluzole, using survival times as the primary measure. The only way to answer this question was by performing larger, lengthier and more comprehensive studies. While the result is deeply disappointing, we now have a clear answer."

More information: Al-Chalabi, A. et al. 'Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial' The Lancet Neurology. doi:10.1016/S1474-4422(13)70037-1

Related Stories

Lithium shows no benefit for people with ALS

date Aug 11, 2010

A new study has found that the drug lithium is not effective in treating people with amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease. The research is published in the August 11, 2010, online issue ...

New ALS drug slips through telling 'phase II' clinical trials

date Jan 04, 2010

A drug already used to treat symptoms of epilepsy has potential to slow the muscle weakening that comes with amyotrophic lateral sclerosis (ALS), scientists report after completing a Phase II clinical trial—an early, small-scale ...

Finger length clue to motor neuron disease

date May 11, 2011

(Medical Xpress) -- People with the commonest form of motor neuron disease (MND) called amyotrophic lateral sclerosis (ALS) are more likely to have relatively long ring fingers, reveals research from the Institute of Psychiatry ...

Recommended for you

Team makes breakthrough in understanding Canavan disease

date 6 hours ago

UC Davis investigators have settled a long-standing controversy surrounding the molecular basis of an inherited disorder that historically affected Ashkenazi Jews from Eastern Europe but now also arises in other populations ...

Finding the body clock's molecular reset button

date 10 hours ago

An international team of scientists has discovered what amounts to a molecular reset button for our internal body clock. Their findings reveal a potential target to treat a range of disorders, from sleep ...

A 'GPS' to navigate the brain's neuronal networks

date 10 hours ago

In new research published today by Nature Methods, scientists from the Hebrew University of Jerusalem and Harvard University have announced a "Neuronal Positioning System" (NPS) that maps the circuitry of the ...

Neurons constantly rewrite their DNA

date 11 hours ago

Johns Hopkins scientists have discovered that neurons are risk takers: They use minor "DNA surgeries" to toggle their activity levels all day, every day. Since these activity levels are important in learning, ...

Hate to diet? It's how we are wired

date 11 hours ago

If you're finding it difficult to stick to a weight-loss diet, scientists at the Howard Hughes Medical Institute's Janelia Research Campus say you can likely blame hunger-sensitive cells in your brain known ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Mar 19, 2013
Lithium has been shown to protect the brain against hippocampal atrophy in depression and stroke damage, so it was plausible it might help ALS patients. Too bad.

The best hope for ALS right now is probably Neuralstem and their NSI-566 drug made from stem cells, which has restored walking ability in some people.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.